Capmatinib Completed Phase 1 Trials for Hepatic Impairment Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02474537INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function